Exane BNP Paribas downgraded Adient from Neutral to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2025 | $14.00 | Neutral | Citigroup |
| 3/4/2025 | $24.00 → $18.00 | Neutral → Underperform | BofA Securities |
| 12/16/2024 | $27.00 → $20.00 | Overweight → Equal Weight | Wells Fargo |
| 11/21/2024 | $30.00 → $24.00 | Buy → Neutral | BofA Securities |
| 9/10/2024 | $24.00 | Hold | Deutsche Bank |
| 9/5/2024 | Peer Perform | Wolfe Research | |
| 7/1/2024 | $26.00 | Underperform → Neutral | Exane BNP Paribas |
| 4/10/2024 | $41.00 → $37.00 | Overweight → Equal Weight | Barclays |
4 - Adient plc (0001670541) (Issuer)
4 - Adient plc (0001670541) (Issuer)
4 - Adient plc (0001670541) (Issuer)
Citigroup initiated coverage of Adient with a rating of Neutral and set a new price target of $14.00
BofA Securities downgraded Adient from Neutral to Underperform and set a new price target of $18.00 from $24.00 previously
Wells Fargo downgraded Adient from Overweight to Equal Weight and set a new price target of $20.00 from $27.00 previously
8-K - Adient plc (0001670541) (Filer)
SD - Adient plc (0001670541) (Filer)
8-K - Adient plc (0001670541) (Filer)